Hepatic steatosis in type 1 diabetes

Review of Diabetic Studies

Volumn 8, Issue 4, 2011, Pages 454-467

  Regnell, Simon E ^a   Lernmark, Åke ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Glycogen synthesis; Hepatic fat; Hepatic steatosis; Hepatocyte; Insulin; NAFLD; Non alcoholic fatty liver disease; Type 1 diabetes

Indexed keywords

AMYLIN; C PEPTIDE; CARBOHYDRATE RESPONSE ELEMENT BINDING PROTEIN; GLUCAGON; GLUCOSE TRANSPORTER 2; GLYCOGEN; HEMOGLOBIN A1C; INSULIN; LIPOPROTEIN; PANCREAS POLYPEPTIDE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ALBUMINURIA; BODY MASS; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE MARKER; ECHOGRAPHY; FATTY ACID OXIDATION; FATTY LIVER; FEASIBILITY STUDY; FIRST PASS EFFECT; GLOMERULUS FILTRATION RATE; GLYCOGEN LIVER LEVEL; GLYCOGEN SYNTHESIS; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; INSULIN CLEARANCE; INSULIN DEGRADATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LIPID ANALYSIS; LIPID STORAGE; LIPOGENESIS; LIVER BIOPSY; LIVER BLOOD FLOW; LIVER CELL; LIVER HISTOLOGY; LIVER METABOLISM; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PINOCYTOSIS; PORTAL VEIN; PREVALENCE; PROGNOSIS; REVIEW;

EID: 84862500687     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2011.8.454     Document Type: Review

References (139)

1. Connor CL. Fatty infiltration of the liver and the development of cirrhosis in diabetes and chronic alcoholism. Am J Pathol 1938. 14(3):347-364.
2. Roden M. Mechanisms of Disease: hepatic steatosis in type 2 diabetes - pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2006. 2(6):335-348.
3. Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 2011. 7(8):456-465.
4. Greenway CV, Stark RD. Hepatic vascular bed. Physiol Rev 1971. 51:23-65.
5. Dauzat M, Lafortune M, Patriquin H, Pomier-Layrargues G. Meal induced changes in hepatic and splanchnic circulation: a noninvasive Doppler study in normal humans. Eur J Appl Physiol Occup Physiol 1994. 68(5):373-380.
6. Rocheleau B, Ethier C, Houle R, Huet PM, Bilodeau M. Hepatic artery buffer response following left portal vein ligation: its role in liver tissue homeostasis. Am J Physiol 1999. 277(5 Pt 1):G1000-G1007.
7. Jakab F, Rath Z, Schmal F, Nagy P, Faller J. The interaction between hepatic arterial and portal venous blood flows; simultaneous measurement by transit time ultrasonic volume flowmetry. Hepatogastroenterology 1995. 42:18-21.
8. Seifalian AM, El-Desoky A, Davidson BR. Hepatic indocyanine green uptake and excretion in a rabbit model of steatosis. Eur Surg Res 2001. 33(3):193-201.
9. Reichen J. The role of the sinusoidal endothelium in liver function. Physiology 1999. 14(3):117-121.
10. Polonsky KS, Given BD, Hirsch L, Shapiro ET, Tillil H, Beebe C, Galloway JA, Frank BH, Karrison T, Van Cauter E. Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 1988. 81:435-441.
11. Waldhäusl W, Bratusch-Marrain P, Gasic S, Korn A, Nowotny P. Insulin production rate following glucose in-gestion estimated by splanchnic C-peptide output in normal man. Diabetologia 1979. 17(4):221-227.
12. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev 1998. 19(5):608-624.
13. White MF, Kahn CR. The insulin signaling system. J Biol Chem 1994. 269(1):1-4.
14. Authier F, Posner BI, Bergeron JJ. Insulin-degrading enzyme. Clin Invest Med 1996. 19(3):149-160.
15. Akiyama H, Yokono K, Shii K, Ogawa W, Taniguchi H, Baba S, Kasuga M. Natural regulatory mechanisms of insulin degradation by insulin degrading enzyme. Biochem Biophys Res Commun 1990. 170(3):1325-1330.
16. Pivovarova O, Gögebakan Ö, Pfeiffer AF, Rudovich N. Glucose inhibits the insulin-induced activation of the insulin-degrading enzyme in HepG2 cell. Diabetologia 2009. 52:1656-1664.
17. Rorsman P, Eliasson L, Renström E, Gromada J, Barg S, Göpel S. The cell physiology of biphasic insulin secretion. News Physiol Sci 2000. 15:72-77.
18. Schmitz O, Rungby J, Edge L, Juhl CB. On high-frequency insulin oscillations. Ageing Res Rev 2008. 7(4):301-305.
19. Hellman B, Gylfe E, Bergsten P, Grapengiesser E, Lund PE, Berts A, Tengholm A, Pipeleers DG, Ling Z. Glucose induces oscillatory Ca2+ signalling and insulin release in human pancreatic beta cells. Diabetologia 1994. 37(Suppl 2):11-20.
20. Porksen N. The in vivo regulation of pulsatile insulin secretion. Diabetologia 2002. 45(1):3-20.
21. 2+ oscillations in clusters of pancreatic (beta)-cells exposed to glucose. Cell Calcium 1991. 12(2-3):229-240.
22. Ravier MA, Güldenagel M, Charollais A, Gjinovci A, Caille D, Söhl G, Wollheim CB, Willecke K, Hen-quin JC, Meda P. Loss of connexin36 channels alters beta-cell coupling, islet synchronization of glucose-induced Ca2+ and insulin oscillations, and basal insulin release. Diabetes 2005. 54(6):1798-1807.
23. Gilon P, Ravier MA, Jonas JC, Henique JC. Control mechanisms of the oscillations of insulin secretion in vitro and in vivo. Diabetes 2002. 51(Suppl 1):S144-S151.
24. Porksen N, Munn S, Ferguson D, O'Brien T, Veld-huis JD, Butler P. Coordinate pulsatile insulin secretion by chronic intraportally transplanted islets in the isolated perfused rat liver. J Clin Invest 1994. 94(1):219-227.
25. Simon C, Brandenberger G. Ultradian oscillations of insulin secretion in humans. Diabetes 2002. 51(Suppl 1):S258-S261.
26. Bergsten P. Pathophysiology of impaired pulsatile insulin release. Diabetes Metab Res Rev 2000. 16(3):179-191.
27. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001. 358(9277):221-229.
28. Czech MP. The nature and regulation of the insulin receptor: Structure and function. Ann Rev Physiol 1985. 47:357-381.
29. Kahn CR, White MF. The insulin receptor and the molecular mechanism of insulin action. J Clin Invest 1988. 82(4):1151-1156.
30. Kasuga M, Karlsson FA, Kahn CR. Insulin stimulates the phosphorylation of the 95,000 dalton subunit of its own receptor. Science 1982. 215:185-187.
31. White MF. The insulin signalling system and the IRS proteins. Diabetologia 1997. 40(Suppl 2):S2-S17.
32. Gonzalez FA, Seth A, Raden DL, Bowman DS, Fay FS, Davis RJ. Serum-induced translocation of mitogen-activated protein kinase to the cell surface ruffling membrane and the nucleus. J Cell Biol 1993. 122(5):1089-1101.
33. Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J 1998. 333(Pt 3):471-490.
34. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004. 166(2):213-223.
35. Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol 2002. 3(4):267-277.
36. Proud CG. Regulation of protein synthesis by insulin. Bio-chem Soc Trans 2006. 34(Pt 2):213-216.
37. Thorens B, Sarkar HK, Kaback HR, Lodish HF. Cloning and functional expression in bacteria of a novel glucose transporter present in liver, intestine, kidney, and beta-pancreatic islet cells, Cell 1988. 55:281-290.
38. Rencurel F, Waeber G, Antoine B, Rocchiccioli F, Maulard P, Girard J, Leturque A. Requirement of glucose metabolism for regulation of glucose transporter type 2 (GLUT2) gene expression in liver, Biochem J 1996. 314(3):903-909.
39. Asano T, Katagiri H, Tsukuda K, Lin LJ, Ishihara H, Yazaki Y, Oka Y. Upregulation of GLUT2 mRNA by glucose, mannose, and fructose in isolated rat hepatocytes. Diabetes 1992. 41:22-25.
40. Postic C, Burcelin R, Rencurel F, Pegorier JP, Lo-izeau M, Girard J, Leturque A. Evidence for a transient inhibitory effect of insulin on GLUT2 expression in the liver: studies in vivo and in vitro. Biochem J 1993. 293(1):119-124.
41. Thorens B, Flier JS, Lodish HF, Kahn BB. Differential regulation of two glucose transporters in rat liver by fasting and refeeding and by diabetes and insulin treatment. Diabetes 1990. 39:712-719.
42. Burcelin R, Eddouks M, Kande J, Assan R, Girard J. Evidence that GLUT-2 mRNA and protein concentrations are decreased by hyperinsulinaemia and increased by hyper-glycaemia in liver of diabetic rats. Biochem J 1992. 288(2):675-679.
43. Barthel A, Schmoll D. Novel concepts in insulin regulation of hepatic gluconeogenesis. Am J Physiol Endo 2003. 285(4):E685-E692.
44. Gold AH. The effect of diabetes and insulin on liver glyco-gen synthetase activation. J Biol Chem 1970. 245(4):903-905.
45. Flatt JP. Use and storage of carbohydrate and fat. Am J Clin Nutr 1995. 61(4):952S-959S.
46. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002. 109(9):1125-1131.
47. Azzout-Marniche D, Becard D, Guichard C, Foretz M, Ferre P, Foufelle F. Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytes. Biochem J 2000. 350(2):389-393.
48. Im SS, Kang SY, Kim SY, Kim HI, Kim JW, Kim KS, Ahn YH. Glucose-stimulated upregulation of GLUT2 gene is mediated by sterol response element-binding pro-tein-1c in the hepatocytes. Diabetes 2005. 54(6):1684-1691.
49. Ferre P, Foufelle F, SREBP-1c Transcription Factor and Lipid Homeostasis: Clinical Perspective. Horm Res 2007. 68:72-82.
50. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004. 114(2):147-152.
51. Weickert MO, Pfeiffer AF. Signalling mechanisms linking hepatic glucose and lipid metabolism. Diabetologia 2006. 49(8):1732-1741.
52. Ruderman NB, Saha AK, Vavvas D, Witters LA. Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol 1999. 276(1 Pt 1):E1-E18.
53. Yamashita H, Takenoshita M, Sakurai M, Bruick RK, Henzel WJ, Shillinglaw W, Arnot D, Uyeda K. A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc Natl Acad Sci USA 2001. 98(16):9116-9121.
54. Elasha H, Alzahrani S, Almalki M, Alomair A, Al-shakweer W. Acute hepatic steatosis: an unusual manifestation of poorly controlled type 1 diabetes. Pract Diab Int 2010. 27(7):282-283.
55. Tobin KA, Ulven SM, Schuster GU, Steineger HH, Andresen SM, Gustafsson JA, Nebb HI. Liver X receptors as insulin-mediating factors in fatty acid and cholesterol biosynthesis. J Biol Chem 2002. 277:10691-10697.
56. Wong RH, Sul HS. Insulin signaling in fatty acid and fat synthesis: a transcriptional perspective. Curr Opin Pharmacol 2010. 10(6):684-691.
57. Casado M, Vallet VS, Kahn A, Vaulont S. Essential role in vivo of upstream stimulatory factors for a normal dietary response of the fatty acid synthase gene in the liver. J Biol Chem 1999. 274(4):2009-2013.
58. Griffin MJ, Wong RH, Pandya N, Sul HS. Direct interaction between USF and SREBP-1c mediates synergistic activation of the fatty-acid synthase promoter. J Biol Chem 2007. 282(8):5453-5467.
59. Softic S, Kirby M, Shroyer N, Kohli R. Hepatic steato-sis in type 2 and type 1 diabetes mellitus is mediated by insulin signaling via fatty acid transport proteins. J Pediatr Gastro-enterol Nutr 2010. 51(Suppl 2):E33-E34.
60. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002. 346(16):1221-1231.
61. Tominaga K, Kurata JH, Chen YK, Fujimoto E, Mi-yagawa S, Abe I, Kusano Y, Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiol-ogical ultrasonographic survey. Dig Dis Sci 1995. 40(9):2002-2009.
62. Franzese A, Vajro P, Argenziano A, Puzziello A, Iannucci MP, Saviano MC. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997. 42(7):1428-1432.
63. Kotronen A, Vehkavaara S, Seppälä-Lindroos A, Bergholm R, Yki-Järvinen H. Effect of liver fat on insulin clearance. Am J Physiol Endo 2007. 293(6):E1709-E1715.
64. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, Goto T, Westerbacka J, Sovijärvi A, Halavaara J, Yki-Järvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002. 87:3023-3028.
65. Ryysy L, Häkkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Järvinen H. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000. 49:749-758.
66. Juurinen L, Tiikainen M, Häkkinen AM, Hakkarainen A, Yki-Järvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endo 2007. 292(3):E829-E835.
67. Neuschwander-Tetri BA. Fatty liver and nonalcoholic steatohepatitis. Clincal cornerstone 2001. 3(6):47-57.
68. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001. 344:495-500.
69. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000. 30(1):48-53.
70. Manton ND, Lipsett J, Moore DJ, Davidson GP, Bourne AJ, Couper RT. Non-alcoholic steatohepatitis in children and adolescents. Med J Aust 2000. 173(9):476-479.
71. Al-Hussaini AA, Sulaiman N, Al-Zahrani M, Alenazi A, Khan M. Prevalence of liver disease among type 1 diabetic children. J Pediatr Gastroenterol Nutr 2010. 51(Suppl 2):E57.
72. El-Karaksy HM, Anwar G, Esmat G, Mansour S, Sa-bry M, Helmy H, El-Hennawy A, Fouad H. Prevalence of hepatic abnormalities in a cohort of Egyptian children with type 1 diabetes mellitus. Pediatr Diabetes 2010. 11(7):462-470.
73. Gaiani S, Avogaro A, Bombonato GC, Bolognesi M, Amor F, Vigili de Kreutzenberg S, Guarneri G, Sacerdoti D. Nonalcoholic fatty liver disease (NAFLD) in nonobese patients with diabetes: Prevalence and relationships with hemodynamic alterations detected with Doppler sono-graphy. J Ultrasound 2009. 12(1):1-5.
74. Targher G, Bertolini L, Padovani R, Rodella S, Zop-pini G, Pichiri I, Sorgato C, Zenari L, Bonora E. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 2010. 53(4):713-718.
75. Targher G, Pichiri I, Zoppini G, Trombetta M, Bonora E. Increased prevalence of chronic kidney disease in patients with type 1 diabetes and non-alcoholic fatty liver. Diabet Med 2012. 29(2):220-226.
76. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002. 123(3):745-750.
77. Pozzato C, Radaelli G, Dall'Asta C, Verduci E, Villa A, Villa C, Scaglioni S, Riva E, Pontiroli AE, Cor-nalba G, et al. MRI in identifying hepatic steatosis in obese children and relation to ultrasonography and metabolic findings. J Pediatr Gastroenterol Nutr 2008. 47(4):493-499.
78. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trail. Diabetes Care 2007. 30:707-712.
79. Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M. Metabolic syndrome in type 1 diabetes: association with diabetic neph-ropathy and glycemic control (the FinnDiane study). Diabetes Care 2005. 28(8):2019-2024.
80. Pambianco G, Costacou T, Orchyard TJ. The prediction of major outcomes of type 1 diabetes: a 12-year prospective study of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate. The Pittsburgh Epidemiology of Diabetes Complications Study Experience. Diabetes Care 2007. 30:1248-1254.
81. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition: a consensus statement from the International Diabetes Federation. Diabet Med 2006. 23:469-480.
82. DeFronzo RA, Simonson D, Ferrannini E. Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1982. 23:313-319.
83. Yki-Järvinen H. Fat in the liver and insulin resistance. Ann Med 2005. 37(5):347-356.
84. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 2006. 22(6):437-443.
85. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005. 172(7):899-905.
86. Mofrad P, Contos MJ, Haquw M, Sargeant C, Fisher RA, Luketic VA. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003. 37(6):1286-1292.
87. West J, Brousil J, Gazis A, Jackson L, Mansell P, Bennett A. Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes mellitus. QJM 2006. 99(12):871-876.
88. Leeds JS, Forman EM, Morely S, Scott, AR, Tesfaye S, Sanders DS. Abnormal liver function tests in patients with type 1 diabetes mellitus: prevalence, clinical correlations and underlying pathologies. Diabet Med 2009. 26:1235-1241.
89. Bulum T, Kolaric B, Duvnjak L, Duvnjak M. Nonalcoholic fatty liver disease markers are associated with insulin resistance in type 1 diabetes. Dig Dis Sci 2011. 56(12):3655-3663.
90. Pociot F, Akolkar B, Concannon P, Erlich HA, Julier C, Morahan G, Nierras CR, Todd JA, Rich SS, Nerup J. Genetics of type 1 diabetes: what's next? Diabetes 2010. 59(7):1561-1571.
91. Melendez-Ramirez LY, Richards RJ, Cefalu WT. Complications of type 1 diabetes. Endocrinol Metab Clin North Am 2010. 39(3):625-640.
92. Targher G, Pichiri I, Zoppini G, Trombetta M, Bonora E, Increased prevalence of cardiovascular disease in type 1 diabetic patients with non-alcoholic fatty liver disease. J Endocrinol Invest 2011. In press.
93. Targher G, Bertolini L, Chonchol M, Rodella S, Zoppini G, Lippi G, Zenari L, Bonora E. Nonalcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and reti-nopathy in type 1 diabetic patients. Diabetologia 2010. 53(7):1341-1348.
94. Verges B. Lipid disorders in type 1 diabetes. Diabetes Metab 2009. 35(5):353-360.
95. Lenaerts J, Verresen L, Van Steenbergen W, Fevery J. Fatty liver hepatitis and type 5 hyperlipoproteinemia in juvenile diabetes mellitus. Case report and review of the literature. J Clin Gastroenterol 1990. 12(1):93-97.
96. Roden M, Bernroider E. Hepatic glucose metabolism in humans - its role in health and disease. Best Pract Res Clin Endocrinol Metab 2003. 17(3):365-383.
97. Cline GW, Rothman DL, Magnusson I, Katz LD, Shulman GI. 13C-nuclear magnetic resonance spectros-copy studies of hepatic glucose metabolism in normal subjects and subjects with insulin-dependent diabetes mellitus. J Clin Invest 1994. 94(6):2369-2376.
98. Bischof MG, Krssak M, Krebs M, Bernroider E, Stingl H, Waldhäusl W, Roden M. Effects of short-term improvement of insulin treatment and glycemia on hepatic glycogen metabolism in type 1 diabetes. Diabetes 2001. 50(2):392-398.
99. Hwang JH, Perseghin G, Rothman DL, Cline GW, Magnusson I, Petersen KF. Impaired net hepatic glyco-gen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. A 13C nuclear magnetic resonance spectroscopy study. J Clin Invest 1995. 95(2):783-787.
100. Matyka K, Dixon RM, Mohn A, Rajagopalan B, Shmueli E, Styles P, Dunger DB. Daytime liver glyco-gen accumulation, measured by 13C magnetic resonance spectroscopy, in young children with Type 1 diabetes melli-tus. Diabet Med 2001. 18(8):659-662.
101. Petersen KF, Laurent D, Rothman DL, Cline GW, Shulman GI. Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans. J Clin Invest 1998. 101(6):1203-1209.
102. Kishore P, Gabriely I, Cui MH, Di Vito J, Gajavelli S, Hwang JH, Shamoon H. Role of hepatic glycogen breakdown in defective counterregulation of hypoglycemia in intensively treated type 1 diabetes. Diabetes 2006. 55(3):659-666.
103. Bronstein HD, Kantrowitz PA, Schaffner F. Marked enlargement of the liver and transient ascites associated with the treatment of diabetic acidosis. N Engl J Med 1959. 261:1314-1318.
104. Munns CF, McCrossin RB, Thomsett MJ, Batch J. Hepatic glycogenosis: reversible hepatomegaly in type 1 diabetes. J Paediatr Child Health 2000. 36(5):449-452.
105. Torbenson M, Chen YY, Brunt E, Cummings OW, Gottfried M, Jakate S. Glycogenic hepatopathy: an under-recognized hepatic complication of diabetes mellitus. Am J Surg Pathol 2006. 30(4):508-513.
106. Aljabri KS, Bokhari SA, Fageeh SM, Alharbi AM, Abaza MA. Glycogen hepatopathy in a 13-year-old male with type 1 diabetes. Ann Saudi Med 2011. 31(4):424-427.
107. Nakamuta M, Ohashi M, Goto K, Tanabe Y, Hi-roshige K, Nawata H. Diabetes mellitus-associated glyco-gen storage hepatomegaly: report of a case and review of the Japanese literature. Fukuoka Igaku Zasshi 1993. 84(7):354-358.
108. Olsson R, Wesslau C, William-Olsson T, Zettergren L. Elevated aminotransferases and alkaline phosphatases in unstable diabetes mellitus without ketoacidosis or hypogly-cemia. J Clin Gastroenterol 1989. 11(5):541-545.
109. Carcione L, Lombardo F, Messina MF, Rosano M, De Luca F. Liver glycogenosis as early manifestation in type 1 diabetes mellitus. Diabetes Nutr Metab 2003. 16(3):182-184.
110. Vallance-Owen J. Liver glycogen in diabetes mellitus. J Clin Pathol 1952. 5(1):42-53
111. Evans RW, Littler TR, Pemberton HS. Glycogen storage in the liver in diabetes mellitus. J Clin Pathol 1955. 8(2):110-113.
112. Abaci A, Bekem O, Unuvar T, Ozer E, Bober E, Arslan N. Hepatic glycogenosis: a rare cause of hepatomegaly in type 1 diabetes mellitus. J Diabetes Complications 2008. 22(5):325-328.
113. Chatila R, West AB. Hepatomegaly and abnormal liver tests due to glycogenosis in adults with diabetes. Medicine (Baltimore) 1996. 75(6):327-333.
114. Unger RH. Role of glucagon in the pathogenesis of diabetes: the status of the controversy. Metabolism 1978. 27(11):1691-1709.
115. Ravier MA, Rutter GA. Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic alpha-cells. Diabetes 2005. 54(6):1789-1797.
116. Aguilar-Parada E, Eisentraut AM, Unger RH. Pancreatic glucagon secretion in normal and diabetic subjects. Am J Med Sci 1969. 257(6):415-419.
117. Unger RH, Orci L. Paracrinology of islets and the paracri-nopathy of diabetes. Proc Natl Acad Sci USA 2010. 107(37):16009-16012.
118. Ramnanan CJ, Edgerton DS, Kraft G, Cherrington AD. Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab 2011. 13(Suppl 1):118-125.
119. Bewsher PD, Ashmore J. Ketogenic and lipolytic effects of glucagon on liver. Biochem Biophys Res Commun 1966. 24(3):431-436.
120. Liljenquist JE, Bomboy JD, Lewis SB, Sinclair-Smith BC, Felts PW, Lacy WW. Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men. J Clin Invest 1974. 53(1):190-197.
121. Berglund ED, Lustig DG, Baheza RA, Hasenour CM, Lee-Young RS, Donahue EP, Lynes SE, Swift LL, Charron MJ, Damon BM, et al. Hepatic glucagon action is essential for exercise-induced reversal of mouse fatty liver. Diabetes 2011. 60(11):2720-2729.
122. Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 1996. 39(4):492-499.
123. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res 2002. 34:504-508.
124. Polonsky KS, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes 1984. 33:486-494.
125. Wahren J. C-peptide: new findings and therapeutic implications in diabetes. Clin Physiol Funct Imaging 2004. 24(4):180-189.
126. Hills CE, Brunskill NJ. C-Peptide and its intracellular signaling. Rev Diabet Stud 2009. 6(3):138-147.
127. Lonovics J, Devitt P, Watson LC, Rayford PL, Thompson JC. Pancreatic polypeptide. A review. Arch Surg 1981. 116(10):1256-1264.
128. Schwartz TW. Pancreatic polypeptide: a unique model for vagal control of endocrine systems. J Auton Nerv Syst 1983. 9(1):99-111.
129. Loba JM, Saryusz-Wolska M, Czupryniak L, Kukulski K. Pancreatic polypeptide secretion in diabetic patients with delayed gastric emptying and autonomic neuropathy. J Diabetes Complications 1997. 11(6):328-333.
130. Skare S, Hanssen KF, Lundqvist G. Increased plasma pancreatic polypeptide (PP) in diabetic ketoacidosis; normalization following treatment. Acta Endocrinol (Copenh) 1980. 93(4):466-469.
131. Nguyen TD, MS Wolfe, Heintz GG, Whitcomb DC, Taylor IL. High affinity binding proteins for pancreatic polypeptide on rat liver membranes. J Biol Chem 1992. 267(13): 9416-9421.
132. Seymour NE, Volpert AR, Andersen DK. Regulation of hepatic insulin receptors by pancreatic polypeptide in fasting and feeding. J Surg Res 1996. 65(1):1-4.
133. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000. 45(10):1929-1934.
134. Targher F, Bertolini L, Padovani R, Rodella S, Tes-sari R, Zenari L, Day C, Arcaro G. Prevalence of nonalcoholic fatty liver disease and Its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007. 30(5):1212-1218.
135. Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, Frier BM, Van Look LA, Johnston GI, Reynolds RM, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 2011. 34(5):1139-1144.
136. Mennesson N, Dumortier J, Hervieu V, Milot L, Guillaud O, Scoazec JY, Pilleul F. Liver steatosis quantification using magnetic resonance imaging: a prospective comparative study with liver biopsy. J Comput Assist Tomogr 2009. 33(5):672-677.
137. Springer F, Machann J, Claussen CD, Schick F, Schwenzer NF. Liver fat content determines by magnetic resonance imaging and spectroscopy. World J Gastroenterol 2010. 16(13):1560-1566.
138. Lecomte M, Gottrand F, Stuckens C, Lecomte-Houcke M. Acute steatosis in an 8-year-old boy with insulin-dependent diabetes mellitus. J Pediatr Gastroenterol Nutr 1997. 25(1):98-100.
139. Mehta SR, Hameed A, Theofanoyiannis P, Robinson S, Valabhji J, Elkeles RS. Non-alcoholic steatohepatitis (NASH) in a patient with type 1 diabetes. Endocrine Abstracts 2005. 10:21.